Telo Genomics Corp (TSE:TELO) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Telo Genomics Corp. showcased its AI-driven CellSelect-Pro tool at the prestigious ASCO 2024 conference, highlighting its ability to improve accuracy and reduce costs in myeloma diagnostic tests. The tool, which is now part of Telo’s TeloViewSMM product and an ongoing clinical trial, has been validated with over 90% accuracy in identifying myeloma cells. The company’s recent publication in the American Journal of Hematology further underscores the potential of TeloView technology in predicting the progression of smoldering multiple myeloma.
For further insights into TSE:TELO stock, check out TipRanks’ Stock Analysis page.